Scar treatment includes topical and injectable products that are used to lessen the appearance of acne scars, surgical scars, and stretch marks. Scars develop when the top layer of the skin is injured due to cuts, burns, or surgical procedures. Scar treatments aim to reduce redness, swelling, itching, and the texture of scars by accelerating the skin’s natural healing process. Topical products such as gels, creams, and ointments containing silicone gels or sheets are applied directly on scars to blend them with the surrounding skin over time. Injectable dermal fillers and laser therapy are commonly used aesthetic procedures to diminish the appearance of raised, depressed, or discolored scars.
The China Scar Treatment Market is estimated to be valued at US$ 16.59 billion in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising aesthetic consciousness among the Chinese population coupled with growing disposable income is a major factor driving the demand for scar treatment products and procedures. According to the American Academy of Dermatology Association, more than 50% of the Chinese population faces the problem of acne or acne scarring. Increasing acceptance of scar treatment therapeutics, availability of advanced scar treatment procedures, and rising need to improve physical appearance are expected to boost the China scar treatment market over the forecast period. Additionally, improving healthcare infrastructure and expanding medical tourism industry in China are favorable factors for market growth. While topical products continue to dominate the market, demand for minimally invasive procedures like laser resurfacing and injectable fillers is growing rapidly due to quick and long-lasting results. Technological advancements in laser and light-based devices have also enhanced treatment outcomes.
Threat of new entrants: Low. The China scar treatment market requires significant investment for R&D to develop new technology and products that can effectively compete with existing brands.
Bargaining power of buyers: Moderate. Buyers have several treatment options to consider and switching costs are relatively low. However, brand loyalty plays a role in their purchase decisions.
Bargaining power of suppliers: Low. The industry has several technology and raw material suppliers without significant differentiation between alternatives.
Threat of new substitutes: Moderate. Alternative treatment options exist like cosmetic procedures but scar treatments have proven efficacy in reducing appearance of scars.
Competitive rivalry: High. The market is dominated by global players investing heavily in developing innovative products and less-invasive techniques.
The China Scar Treatment Market Size is expected to witness high growth, exhibiting a CAGR of 13% over the forecast period, due to increasing medical tourism and rising disposable income in the region. Treatment procedures are becoming more effective and less invasive, driving mainstream adoption.
Regionally, South China is expected to dominate the market through 2030 on account of higher concentration of cosmetic clinics and dermatologists in provinces like Guangdong and Fujian. North and Central China will exhibit fastest growth during the forecast period owing to expansion of private healthcare sector in these regions.
Key players operating in the China scar treatment market are Smith & Nephew plc, Merz, Inc., Lumenis, Enaltus LLC, Sonoma Pharmaceuticals, Inc., Mölnlycke Health Care, Cynosure, Inc., CCA Industries, Inc., Scarheal, Inc., NewMedical Technology, Inc., and Suneva Medical, Inc. Players are focusing on new product launches with the latest technologies in non-ablative fractionated lasers and dermal fillers to garner higher market share.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it